

# Preleukaemic clonal haemopoiesis and risk of therapy-related acute myeloid leukaemia: a case-control study

Lancet Oncology, The

18, 100-111

DOI: [10.1016/S1470-2045\(16\)30626-x](https://doi.org/10.1016/S1470-2045(16)30626-X)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Somatic TP53 mutations characterize preleukemic stem cells in acute myeloid leukemia. <i>Blood</i> , 2017, 129, 2587-2591.	0.6	44
2	Donor-engrafted CHIP is common among stem cell transplant recipients with unexplained cytopenias. <i>Blood</i> , 2017, 130, 91-94.	0.6	78
3	Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study. <i>Lancet Oncology</i> , The, 2017, 18, 112-121.	5.1	249
4	CHIP, ICUS, CCUS and other four-letter words. <i>Leukemia</i> , 2017, 31, 1869-1871.	3.3	71
5	Characteristics and outcome of patients with therapy-related acute promyelocytic leukemia front-line treated with or without arsenic trioxide. <i>Leukemia</i> , 2017, 31, 2347-2354.	3.3	32
6	Favorable impact of allogeneic stem cell transplantation in patients with therapy-related myelodysplasia regardless of TP53 mutational status. <i>Haematologica</i> , 2017, 102, 2030-2038.	1.7	26
7	Clonal evolution in leukemia. <i>Nature Medicine</i> , 2017, 23, 1135-1145.	15.2	93
8	Clonality in context: hematopoietic clones in their marrow environment. <i>Blood</i> , 2017, 130, 2363-2372.	0.6	74
9	Therapy-related myeloid neoplasms: when genetics and environment collide. <i>Nature Reviews Cancer</i> , 2017, 17, 513-527.	12.8	270
10	Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes. <i>Cell Stem Cell</i> , 2017, 21, 374-382.e4.	5.2	578
13	Ultra-sensitive Sequencing Identifies High Prevalence of Clonal Hematopoiesis-Associated Mutations throughout Adult Life. <i>American Journal of Human Genetics</i> , 2017, 101, 50-64.	2.6	210
14	Copy number alterations detected as clonal hematopoiesis of indeterminate potential. <i>Blood Advances</i> , 2017, 1, 1031-1036.	2.5	30
15	Preleukemic Hematopoietic Stem Cells in Human Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2017, 7, 263.	1.3	39
16	Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions. <i>Oncotarget</i> , 2017, 8, 73483-73500.	0.8	153
17	Risk and timing of cardiovascular death among patients with myelodysplastic syndromes. <i>Blood Advances</i> , 2017, 1, 2032-2040.	2.5	53
18	La présence d'altérations clonales de signification indéterminées permet-elle de prédire la survenue d'une hémopathie secondaire à un traitement pour cancer chez les patients de plus de 70 ans? <i>Hématologie</i> , 2017, 23, 20-21.	0.0	0
19	Uncoding the genetic heterogeneity of myelodysplastic syndrome. <i>Hematology American Society of Hematology Education Program</i> , 2017, 2017, 447-452.	0.9	26
20	Hematopoietic lineage distribution and evolutionary dynamics of clonal hematopoiesis. <i>Leukemia</i> , 2018, 32, 1908-1919.	3.3	137

#	ARTICLE	IF	CITATIONS
21	Ups and downs of CHIP. <i>Blood</i> , 2018, 131, 1773-1774.	0.6	0
22	Detection of clonal hematopoiesis of indeterminate potential in clinical sequencing of solid tumor specimens. <i>Blood</i> , 2018, 131, 2501-2505.	0.6	57
23	Clonal Hematopoiesis and Evolution to Hematopoietic Malignancies. <i>Cell Stem Cell</i> , 2018, 22, 157-170.	5.2	345
24	Cellular stressors contribute to the expansion of hematopoietic clones of varying leukemic potential. <i>Nature Communications</i> , 2018, 9, 455.	5.8	150
25	Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide. <i>Blood</i> , 2018, 131, 1820-1832.	0.6	40
26	Early detection and evolution of preleukemic clones in therapy-related myeloid neoplasms following autologous SCT. <i>Blood</i> , 2018, 131, 1846-1857.	0.6	35
27	Age-related clonal hematopoiesis and monoclonal B-cell lymphocytosis/chronic lymphocytic leukemia: a new association?. <i>Haematologica</i> , 2018, 103, 751-752.	1.7	6
28	New Insights from Studies of Clonal Hematopoiesis. <i>Clinical Cancer Research</i> , 2018, 24, 4633-4642.	3.2	76
29	Mutation analysis of therapy-related myeloid neoplasms. <i>Cancer Genetics</i> , 2018, 222-223, 38-45.	0.2	11
30	Myelodysplastic syndromes: 2018 update on diagnosis, risk stratification and management. <i>American Journal of Hematology</i> , 2018, 93, 129-147.	2.0	154
31	Risk of developing chronic myeloid neoplasms in well-differentiated thyroid cancer patients treated with radioactive iodine. <i>Leukemia</i> , 2018, 32, 952-959.	3.3	30
32	Comprehensive genomic characterization dissects the complex biology of a case of synchronous Burkitt lymphoma and myeloid malignancy with shared hematopoietic ancestry. <i>Leukemia and Lymphoma</i> , 2018, 59, 992-995.	0.6	2
33	Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2018, 36, 1788-1797.	0.8	156
34	Acute Myeloid Leukemia: The Good, the Bad, and the Ugly. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 555-573.	1.8	71
35	Sustained clonal hematopoiesis by HLA-lacking hematopoietic stem cells without driver mutations in aplastic anemia. <i>Blood Advances</i> , 2018, 2, 1000-1012.	2.5	20
36	Age-related clonal hematopoiesis: implications for hematopoietic stem cell transplantation. <i>Current Opinion in Hematology</i> , 2018, 25, 441-445.	1.2	6
37	Therapy-related myeloid neoplasms: clinical perspectives. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 5909-5915.	1.0	12
38	The impact of new drugs for breast and ovarian cancer on the occurrence of therapy-related myeloid neoplasms: Understanding the baseline incidence. <i>Gynecologic Oncology</i> , 2018, 151, 187-189.	0.6	4

#	ARTICLE	IF	CITATIONS
39	PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy. <i>Cell Stem Cell</i> , 2018, 23, 700-713.e6.	5.2	272
40	Clinical consequences of clonal hematopoiesis of indeterminate potential. <i>Hematology American Society of Hematology Education Program</i> , 2018, 2018, 264-269.	0.9	83
41	Clinical consequences of clonal hematopoiesis of indeterminate potential. <i>Blood Advances</i> , 2018, 2, 3404-3410.	2.5	149
42	Secondary primary cancers before and after myeloid neoplasia: a two-way street. <i>Lancet Haematology</i> , 2018, 5, e328-e329.	2.2	0
43	ASC specks: a biomarker for myelodysplastic syndromes?. <i>Lancet Haematology</i> , 2018, 5, e379-e380.	2.2	2
44	Acute myeloid leukaemia. <i>Lancet</i> , 2018, 392, 593-606.	6.3	512
45	Clonal Hematopoiesis in Aging. <i>Current Stem Cell Reports</i> , 2018, 4, 209-219.	0.7	18
46	Incidence and survival of therapy related myeloid neoplasm in United States. <i>Leukemia Research</i> , 2018, 71, 95-99.	0.4	24
47	Clinical Implications of Clonal Hematopoiesis. <i>Mayo Clinic Proceedings</i> , 2018, 93, 1122-1130.	1.4	81
48	Chronic Myeloid Leukemia Following Treatment for Primary Neoplasms or Other Medical Conditions. <i>American Journal of Clinical Pathology</i> , 2018, 150, 246-258.	0.4	8
49	Ludwig Boltzmann Cluster Oncology (LBC ONC): first 10 years and future perspectives. <i>Wiener Klinische Wochenschrift</i> , 2018, 130, 517-529.	1.0	3
50	Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes. <i>Nature Communications</i> , 2018, 9, 2670.	5.8	79
51	Therapy-related acute myeloid leukemia developing 14 years after allogeneic hematopoietic stem cell transplantation, from a persistent R882H- DNMT3A mutated clone of patient origin. <i>Experimental and Molecular Pathology</i> , 2018, 105, 139-143.	0.9	2
52	MYBL2 Supports DNA Double Strand Break Repair in Hematopoietic Stem Cells. <i>Cancer Research</i> , 2018, 78, 5767-5779.	0.4	30
53	Identification of Clonal Hematopoiesis Mutations in Solid Tumor Patients Undergoing Unpaired Next-Generation Sequencing Assays. <i>Clinical Cancer Research</i> , 2018, 24, 5918-5924.	3.2	84
54	ICUS, IDUS, CHIP and CCUS: Diagnostic Criteria, Separation from MDS and Clinical Implications. <i>Pathobiology</i> , 2019, 86, 30-38.	1.9	71
56	Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study. <i>Blood Advances</i> , 2019, 3, 508-518.	2.5	62
57	Premalignant Clonal Hematopoietic Proliferations. <i>American Journal of Clinical Pathology</i> , 2019, 152, 347-358.	0.4	3

#	ARTICLE	IF	CITATIONS
58	Myelodysplastic Syndromes: An Update on Pathophysiology and Management. , 0, , .		0
59	From clonal hematopoiesis to myeloid leukemia and what happens in between: Will improved understanding lead to new therapeutic and preventive opportunities?. Blood Reviews, 2019, 37, 100587.	2.8	23
61	Clonal hematopoiesis in human aging and disease. Science, 2019, 366, .	6.0	590
62	The Clinical Challenge of Idiopathic Cytopenias of Undetermined Significance (ICUS) and Clonal Cytopenias of Undetermined Significance (CCUS). Current Hematologic Malignancy Reports, 2019, 14, 536-542.	1.2	29
63	Mutations found in cell-free DNA s of patients with malignant lymphoma at remission can derive from clonal hematopoiesis. Cancer Science, 2019, 110, 3375-3381.	1.7	16
64	CHIPing Away at Breast Cancer. Journal of the National Cancer Institute, 2019, 112, 10-11.	3.0	0
65	Comparison of therapy-related myelodysplastic syndrome with ring sideroblasts and de novo myelodysplastic syndrome with ring sideroblasts. Leukemia Research, 2019, 86, 106227.	0.4	2
66	Clonal hematopoiesis: Pre-cancer PLUS. Advances in Cancer Research, 2019, 141, 85-128.	1.9	35
67	Molecular and cytogenetic characteristics of myeloid malignancies following luminal gastrointestinal cancer. Leukemia Research, 2019, 82, 19-23.	0.4	0
68	Clonal Hematopoiesis and risk of Acute Myeloid Leukemia. Best Practice and Research in Clinical Haematology, 2019, 32, 177-185.	0.7	15
69	The Karolinska experience of autologous stem-cell transplantation for lymphoma: a population-based study of all 433 patients 1994-2016. Experimental Hematology and Oncology, 2019, 8, 7.	2.0	14
70	Emerging patterns in clonal haematopoiesis. Journal of Clinical Pathology, 2019, 72, 453-459.	1.0	2
72	Molecular genetic testing in the diagnosis of myeloid neoplasms. Diagnostic Histopathology, 2019, 25, 249-259.	0.2	1
73	Functional Dominance of CHIP-Mutated Hematopoietic Stem Cells in Patients Undergoing Autologous Transplantation. Cell Reports, 2019, 27, 2022-2028.e3.	2.9	44
74	CHIP, CCUS, and Other Acronyms: Definition, Implications, and Impact on Practice. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, 400-410.	1.8	58
75	Prevalence and characteristics of likely-somatic variants in cancer susceptibility genes among individuals who had hereditary pan-cancer panel testing. Cancer Genetics, 2019, 235-236, 31-38.	0.2	23
76	Challenges in the diagnosis and treatment of secondary acute myeloid leukemia. Critical Reviews in Oncology/Hematology, 2019, 138, 6-13.	2.0	16
77	Long-term overall and progression-free survival after pentostatin, cyclophosphamide and rituximab therapy for indolent non-Hodgkin lymphoma. British Journal of Haematology, 2019, 185, 670-678.	1.2	7

#	ARTICLE	IF	CITATIONS
78	Connections Between Clonal Hematopoiesis, Cardiovascular Disease, and Cancer. <i>JAMA Cardiology</i> , 2019, 4, 380.	3.0	42
79	Clonal haematopoiesis of indeterminate potential among cancer survivors exposed to myelotoxic chemotherapy. <i>British Journal of Haematology</i> , 2019, 186, e31-e35.	1.2	17
80	Managing Clonal Hematopoiesis in Patients With Solid Tumors. <i>Journal of Clinical Oncology</i> , 2019, 37, 7-11.	0.8	60
81	Clonal Hematopoiesis of Indeterminate Potential. <i>Journal of Clinical Oncology</i> , 2019, 37, 419-422.	0.8	18
82	Clonal hematopoiesis and preleukemia—Genetics, biology, and clinical implications. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 828-838.	1.5	18
83	Role of Donor Clonal Hematopoiesis in Allogeneic Hematopoietic Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2019, 37, 375-385.	0.8	163
84	Clonal Hematopoiesis with Oncogenic Potential (CHOP): Separation from CHIP and Roads to AML. <i>International Journal of Molecular Sciences</i> , 2019, 20, 789.	1.8	50
85	TP53 and therapy-related myeloid neoplasms. <i>Best Practice and Research in Clinical Haematology</i> , 2019, 32, 98-103.	0.7	9
86	Stem cell damage after chemotherapy- can we do better?. <i>Best Practice and Research in Clinical Haematology</i> , 2019, 32, 31-39.	0.7	6
87	Germline polymorphisms and the risk of therapy-related myeloid neoplasms. <i>Best Practice and Research in Clinical Haematology</i> , 2019, 32, 24-30.	0.7	5
88	Clinicopathological aspects of therapy-related acute myeloid leukemia and myelodysplastic syndrome. <i>Best Practice and Research in Clinical Haematology</i> , 2019, 32, 3-12.	0.7	12
89	Clonal Hematopoiesis and therapy related MDS/AML. <i>Best Practice and Research in Clinical Haematology</i> , 2019, 32, 13-23.	0.7	17
90	Stem cell mutations can be detected in myeloma patients years before onset of secondary leukemias. <i>Blood Advances</i> , 2019, 3, 3962-3967.	2.5	12
91	When should transplant physicians think about familial blood cancers?. <i>Advances in Cell and Gene Therapy</i> , 2019, 2, e68.	0.6	4
92	High-accuracy liquid biopsies. <i>Nature Medicine</i> , 2019, 25, 1820-1821.	15.2	12
93	Hereditary cancer testing challenges: assembling the analytical pieces to solve the patient clinical puzzle. <i>Future Oncology</i> , 2019, 15, 65-79.	1.1	4
94	Cord blood transplantation is associated with good outcomes in secondary Acute Myeloid Leukaemia in first remission. <i>Journal of Internal Medicine</i> , 2019, 285, 446-454.	2.7	4
95	Anemia in the Young and Old. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
96	Clinical implications of subclonal <i>TP53</i> mutations in acute myeloid leukemia. <i>Haematologica</i> , 2019, 104, 516-523.	1.7	65
97	Persistent clonal cytogenetic abnormality with del(20q) from an initial diagnosis of acute promyelocytic leukemia. <i>International Journal of Hematology</i> , 2020, 111, 311-316.	0.7	1
98	Molecular characterization of a second myeloid neoplasm developing after treatment for acute myeloid leukemia. <i>Leukemia</i> , 2020, 34, 811-820.	3.3	6
99	Cardiovascular Disease, Aging, and Clonal Hematopoiesis. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2020, 15, 419-438.	9.6	94
100	Clonal Hematopoiesis and Premalignant Diseases. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2020, 10, a035675.	2.9	10
101	Graft-versus-host disease and graft-versus-leukaemia effects in secondary acute myeloid leukaemia: a retrospective, multicentre registry analysis from the Acute Leukaemia Working Party of the EBMT. <i>British Journal of Haematology</i> , 2020, 188, 428-437.	1.2	12
102	A substantial proportion of apparently heterozygous <i>TP53</i> pathogenic variants detected with a next-generation sequencing hereditary panel are acquired somatically. <i>Human Mutation</i> , 2020, 41, 203-211.	1.1	19
103	Genomics of therapy-related myeloid neoplasms. <i>Haematologica</i> , 2020, 105, e98-e101.	1.7	23
104	Unraveling cancer lineage drivers in squamous cell carcinomas. , 2020, 206, 107448.		20
105	Assessing clonal haematopoiesis: clinical burdens and benefits of diagnosing myelodysplastic syndrome precursor states. <i>Lancet Haematology</i> , 2020, 7, e73-e81.	2.2	45
106	Clonal hematopoiesis as a model for premalignant changes during aging. <i>Experimental Hematology</i> , 2020, 83, 48-56.	0.2	56
107	How to address second and therapy-related acute myelogenous leukaemia. <i>British Journal of Haematology</i> , 2020, 188, 116-128.	1.2	18
108	Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics. <i>Nature Communications</i> , 2020, 11, 5327.	5.8	208
109	Survival Improvement over Time of 960 s-AML Patients Included in 13 EORTC-GIMEMA-HOVON Trials. <i>Cancers</i> , 2020, 12, 3334.	1.7	6
110	Fidelity of peripheral blood for monitoring genomics and tumor immune microenvironment in myelodysplastic syndromes. <i>EJHaem</i> , 2020, 1, 552-557.	0.4	3
111	Mutations in myelodysplastic syndromes: Core abnormalities and CHIPping away at the edges. <i>International Journal of Laboratory Hematology</i> , 2020, 42, 671-684.	0.7	7
112	Clonal hematopoiesis and non-hematologic disorders. <i>Blood</i> , 2020, 136, 1606-1614.	0.6	71
113	Clonal hematopoiesis and risk for hematologic malignancy. <i>Blood</i> , 2020, 136, 1599-1605.	0.6	35

#	ARTICLE	IF	CITATIONS
114	What To Tell Your Patient With Clonal Hematopoiesis And Why: Insights From Two Specialized Clinics. <i>Blood</i> , 2020, 136, 1623-1631.	0.6	23
115	Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management. <i>American Journal of Hematology</i> , 2020, 95, 1399-1420.	2.0	119
116	Clonal Hematopoiesis of Indeterminate Potential as a Novel Risk Factor for Donor-Derived Leukemia. <i>Stem Cell Reports</i> , 2020, 15, 279-291.	2.3	10
117	Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial. <i>Nature Medicine</i> , 2020, 26, 1852-1858.	15.2	104
118	Cytotoxic Therapyâ€™Induced Effects on Both Hematopoietic and Marrow Stromal Cells Promotes Therapy-Related Myeloid Neoplasms. <i>Blood Cancer Discovery</i> , 2020, 1, 32-47.	2.6	16
119	Chasing ctDNA in Patients With Sarcoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, e351-e360.	1.8	8
120	Clinical Applications of Chromosomal Microarray Testing in Myeloid Malignancies. <i>Current Hematologic Malignancy Reports</i> , 2020, 15, 194-202.	1.2	7
121	Quantitative and Qualitative QC of Next-Generation Sequencing for Detecting Somatic Variants: An Example of Detecting Clonal Hematopoiesis of Indeterminate Potential. <i>Clinical Chemistry</i> , 2020, 66, 832-841.	1.5	3
122	Clonal hematopoiesis evolves from pretreatment clones and stabilizes after end of chemotherapy in patients with MCL. <i>Blood</i> , 2020, 135, 2000-2004.	0.6	26
123	Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. <i>Nature Communications</i> , 2020, 11, 2996.	5.8	98
124	Exposure to ibritumomab tiuxetan and incidence of treatment-related myeloid neoplasms among older patients with B-cell lymphoma: a population-based study. <i>Leukemia</i> , 2020, 34, 2794-2797.	3.3	10
125	Clinical impact of clonal hematopoiesis in patients with lymphoma undergoing ASCT: a national population-based cohort study. <i>Leukemia</i> , 2020, 34, 3256-3268.	3.3	46
126	The evolutionary dynamics and fitness landscape of clonal hematopoiesis. <i>Science</i> , 2020, 367, 1449-1454.	6.0	294
127	Normal Hematopoiesis Is a Balancing Act of Self-Renewal and Regeneration. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2020, 10, a035519.	2.9	29
128	Genetic and Genomic Landscape of Secondary and Therapy-Related Acute Myeloid Leukemia. <i>Genes</i> , 2020, 11, 749.	1.0	30
129	Clonal hematopoiesis and inflammation: Partners in leukemogenesis and comorbidity. <i>Experimental Hematology</i> , 2020, 83, 85-94.	0.2	77
130	Clonal hematopoiesis in cancer. <i>Experimental Hematology</i> , 2020, 83, 105-112.	0.2	24
131	The Clinical Management of Clonal Hematopoiesis. <i>Hematology/Oncology Clinics of North America</i> , 2020, 34, 357-367.	0.9	42



#	ARTICLE	IF	CITATIONS
132	Cancer as a disease of old age: changing mutational and microenvironmental landscapes. <i>British Journal of Cancer</i> , 2020, 122, 943-952.	2.9	153
133	ASXL1 mutation in clonal hematopoiesis. <i>Experimental Hematology</i> , 2020, 83, 74-84.	0.2	30
134	Second malignancies in multiple myeloma; emerging patterns and future directions. <i>Best Practice and Research in Clinical Haematology</i> , 2020, 33, 101144.	0.7	27
135	Clonal selection in therapy-related myelodysplastic syndromes and acute myeloid leukemia under azacitidine treatment. <i>European Journal of Haematology</i> , 2020, 104, 488-498.	1.1	6
136	Predisposed genomic instability in pre-treatment bone marrow evolves to therapy-related myeloid neoplasms in malignant lymphoma. <i>Haematologica</i> , 2020, 105, e337-e339.	1.7	7
137	Assessment of Therapy-Related Myeloid Neoplasms in Patients With Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy. <i>JAMA Oncology</i> , 2020, 6, 1086.	3.4	30
138	Clonal hematopoiesis predicts development of therapy-related myeloid neoplasms post autologous stem cell transplantation. <i>Blood Advances</i> , 2020, 4, 885-892.	2.5	33
139	Acute Leukemias. <i>Hematologic Malignancies</i> , 2021, , .	0.2	2
140	Protein phosphatase, Mg <sup>2+</sup> /Mn <sup>2+</sup> -dependent 1D (PPM1D) mutations in haematological cancer. <i>British Journal of Haematology</i> , 2021, 192, 697-705.	1.2	7
141	Absence of a common founder mutation in patients with cooccurring myelodysplastic syndrome and plasma cell disorder. <i>Blood</i> , 2021, 137, 1260-1263.	0.6	5
142	Initial report of a phase II study with R-FND followed by ibritumomab tiuxetan radioimmunotherapy and rituximab maintenance in patients with untreated high-risk follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 58-67.	0.6	2
143	Integrating clonal haematopoiesis into geriatric oncology: The ARCH between aging, cardiovascular disease and malignancy. <i>Journal of Geriatric Oncology</i> , 2021, 12, 479-482.	0.5	2
144	Hereditary cancer syndrome-associated pathogenic variants are common in patients with hematologic malignancies subsequent to primary solid cancer. <i>Journal of Cancer</i> , 2021, 12, 4288-4294.	1.2	0
145	<i>TP53</i> mutated myeloid malignancies and their treatment strategy. <i>Journal of Hematopoietic Cell Transplantation</i> , 2021, 10, 7-15.	0.1	0
146	Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative Study*. <i>British Journal of Haematology</i> , 2021, 192, 832-842.	1.2	15
147	From Clonal Hematopoiesis to Therapy-Related Myeloid Neoplasms: The Silent Way of Cancer Progression. <i>Biology</i> , 2021, 10, 128.	1.3	5
148	Insights into clonal hematopoiesis and its relation to cancer risk. <i>Current Opinion in Genetics and Development</i> , 2021, 66, 63-69.	1.5	20
149	Therapy-related leukaemias with balanced translocations can arise from pre-existing clonal haematopoiesis. <i>Leukemia</i> , 2021, 35, 2407-2411.	3.3	3

#	ARTICLE	IF	CITATIONS
150	Outcome of Tâ€cell acute lymphoblastic leukemia/lymphoma: Focus on <scp>nearâ€ETP</scp> phenotype and differential impact of nelarabine. American Journal of Hematology, 2021, 96, 589-598.	2.0	42
151	Controversies in the recent (2016) World Health Organization classification of acute myeloid leukemia. Best Practice and Research in Clinical Haematology, 2021, 34, 101249.	0.7	9
152	Gene Editing of Hematopoietic Stem Cells: Hopes and Hurdles Toward Clinical Translation. Frontiers in Genome Editing, 2021, 3, 618378.	2.7	27
153	Whatâ€™s new in the pathogenesis and treatment of therapy-related myeloid neoplasms. Blood, 2021, 138, 749-757.	0.6	23
154	Clonal haematopoiesis of emerging significance. Pathology, 2021, 53, 300-311.	0.3	9
155	Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia. Nature Communications, 2021, 12, 2607.	5.8	61
156	Clonal hematopoiesis and therapy-related myeloid neoplasms following neuroblastoma treatment. Blood, 2021, 137, 2992-2997.	0.6	19
157	Germline risk of clonal haematopoiesis. Nature Reviews Genetics, 2021, 22, 603-617.	7.7	48
158	Loss of a 7q gene, <i>CUX1</i>, disrupts epigenetically driven DNA repair and drives therapy-related myeloid neoplasms. Blood, 2021, 138, 790-805.	0.6	13
159	Cumulative exposure to melphalan chemotherapy and subsequent risk of developing acute myeloid leukemia and myelodysplastic syndromes in patients with multiple myeloma. European Journal of Haematology, 2021, 107, 275-282.	1.1	8
160	PARP inhibitor associated treatment related myeloid neoplasms: What was a â€Rareâ€ complication may be less so. Gynecologic Oncology, 2021, 161, 639-641.	0.6	3
161	Clonal hematopoiesis and bone marrow failure syndromes. Best Practice and Research in Clinical Haematology, 2021, 34, 101273.	0.7	6
162	Pancytopenia in a Patient With Metastatic Well-Differentiated Neuroendocrine Tumor After Peptide Receptor Radionuclide Therapy. JAMA Oncology, 2021, 7, 1060.	3.4	1
163	Diagnostic Challenge and Clinical Dilemma: The Long Reach of Clonal Hematopoiesis. Clinical Chemistry, 2021, 67, 1062-1070.	1.5	0
164	Clonal Hematopoiesis: From Mechanisms to Clinical Intervention. Cancer Discovery, 2021, 11, 2987-2997.	7.7	30
165	Clonal hematopoiesis and myeloid malignancies. Current Opinion in Hematology, 2021, Publish Ahead of Print, 347-355.	1.2	4
166	Molecular Landscape of Therapy-related Myeloid Neoplasms in Patients Previously Treated for Gynecologic and Breast Cancers. HemaSphere, 2021, 5, e632.	1.2	10
168	Therapy-Related Myeloid Neoplasms in 109 Patients Following Radiation Monotherapy. Blood Advances, 2021, 5, 4140-4148.	2.5	6

#	ARTICLE	IF	CITATIONS
169	Mutational patterns and their correlation to CHIP-related mutations and age in hematological malignancies. <i>Blood Advances</i> , 2021, 5, 4426-4434.	2.5	30
170	Epidemiology and Etiology of AML. <i>Hematologic Malignancies</i> , 2021, , 1-22.	0.2	3
171	Genomic Landscape and Clonal Evolution of AML. <i>Hematologic Malignancies</i> , 2021, , 103-118.	0.2	0
172	Secondary AML. <i>Hematologic Malignancies</i> , 2021, , 71-101.	0.2	0
173	Comprehensive T cell repertoire characterization of non-small cell lung cancer. <i>Nature Communications</i> , 2020, 11, 603.	5.8	140
178	Chipping in on clonal hematopoiesis. <i>Oncotarget</i> , 2017, 8, 84637-84638.	0.8	1
179	Myelodysplastic syndromes: moving towards personalized management. <i>Haematologica</i> , 2020, 105, 1765-1779.	1.7	52
180	Classification of acute myeloid leukemia. <i>Blood Research</i> , 2020, 55, S1-S4.	0.5	35
181	Preexisting <i>TP53</i> -Variant Clonal Hematopoiesis and Risk of Secondary Myeloid Neoplasms in Patients With High-grade Ovarian Cancer Treated With Rucaparib. <i>JAMA Oncology</i> , 2021, 7, 1772.	3.4	44
182	Advances in acute myeloid leukemia. <i>BMJ, The</i> , 2021, 375, n2026.	3.0	177
183	Poly(ADP-Ribose) Polymerase Inhibitors and Myeloid Neoplasm Risk—Clues to a Mechanistic Connection?. <i>JAMA Oncology</i> , 2021, 7, 1763.	3.4	0
185	Hematopoiesis and Aging. , 2018, , 1-24.		0
186	Clonal Hematopoiesis and Cytopenias in the Elderly. , 2019, , 195-212.		0
187	Epidemiology, Etiology, and Clinical Presentation of Myelodysplastic Syndromes. , 2020, , 3-17.		2
188	Impact of luteinizing hormone suppression on hematopoietic recovery after intensive chemotherapy in patients with leukemia. <i>Haematologica</i> , 2021, 106, 0-0.	1.7	6
189	Hematopoiesis and Aging. , 2020, , 305-328.		0
190	Prostate cancer research in the 21st century; report from the 2021 Coffey—Holden prostate cancer academy meeting. <i>Prostate</i> , 2021, , .	1.2	2
191	Clinical Presentation, Diagnosis, and Classification of Acute Myeloid Leukemia. <i>Hematologic Malignancies</i> , 2021, , 11-55.	0.2	0

#	ARTICLE	IF	CITATIONS
194	Therapy-related acute myeloid leukemia and its prevention. American Journal of Blood Research, 2020, 10, 416-433.	0.6	1
195	Emerging trends of therapy related myeloid neoplasms following modern cancer therapeutics in the United States. Scientific Reports, 2021, 11, 23284.	1.6	3
196	Differential expression of circular RNAs in plasma exosomes from patients with ankylosing spondylitis. Cell Biology International, 2022, 46, 649-659.	1.4	9
198	Association of clonal hematopoiesis mutations with clinical outcomes: A systematic review and meta-analysis. American Journal of Hematology, 2022, 97, 411-420.	2.0	11
199	Bone Marrow Surveillance of Pediatric Cancer Survivors Identifies Clones that Predict Therapy-Related Leukemia. Clinical Cancer Research, 2022, 28, 1614-1627.	3.2	4
200	Diagnosis and treatment of therapy-related acute myeloid leukemia. Critical Reviews in Oncology/Hematology, 2022, 171, 103607.	2.0	19
201	Clonal evolution in patients developing therapy-related myeloid neoplasms following autologous stem cell transplantation. Bone Marrow Transplantation, 2022, 57, 460-465.	1.3	4
202	The emerging importance and evolving understanding of clonal hematopoiesis in multiple myeloma. Seminars in Oncology, 2022, 49, 19-26.	0.8	5
203	Mutant <i>PPM1D</i> - and <i>TP53</i> -Driven Hematopoiesis Populates the Hematopoietic Compartment in Response to Peptide Receptor Radionuclide Therapy. JCO Precision Oncology, 2022, 6, e2100309.	1.5	15
204	Molecular and genomic landscapes in secondary & therapy related acute myeloid leukemia. American Journal of Blood Research, 2021, 11, 472-497.	0.6	2
205	Two Cases of Myelodysplastic Syndrome and Neck Infection After Chemoradiotherapy for Hypopharyngeal Carcinoma. Practica Otologica, 2022, 115, 307-314.	0.0	0
206	Exploring the Associations Between Clonal Hematopoiesis of Indeterminate Potential, Myeloid Malignancy, and Atherosclerosis. Methods in Molecular Biology, 2022, 2419, 73-88.	0.4	3
207	Epidemiologic Outlook of Therapy-Related Myeloid Neoplasms and Selection of High-Risk Patients: Korean Nationwide Study. SSRN Electronic Journal, 0, , .	0.4	0
208	Second Cancer Onset in Myeloproliferative Neoplasms: What, When, Why?. International Journal of Molecular Sciences, 2022, 23, 3177.	1.8	5
209	Therapy-related myeloid neoplasms with normal karyotype show distinct genomic and clinical characteristics compared to their counterparts with abnormal karyotype. British Journal of Haematology, 2022, 197, 736-744.	1.2	6
211	Combination strategies to promote sensitivity to cytarabine-induced replication stress in acute myeloid leukemia with and without DNMT3A mutations. Experimental Hematology, 2022, , .	0.2	2
212	Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy. Nature Medicine, 2022, 28, 557-567.	15.2	26
213	Somatic Mutations of Hematopoietic Cells Are an Additional Mechanism of Body Aging, Conducive to Comorbidity and Increasing Chronification of Inflammation. Biomedicines, 2022, 10, 782.	1.4	3

#	ARTICLE	IF	CITATIONS
214	Clonal haematopoiesis as a risk factor for therapy-related myeloid neoplasms in patients with chronic lymphocytic leukaemia treated with chemo- (immuno)therapy. <i>British Journal of Haematology</i> , 2022, 198, 103-113.	1.2	7
217	Lenalidomide promotes the development of <i>TP53</i> -mutated therapy-related myeloid neoplasms. <i>Blood</i> , 2022, 140, 1753-1763.	0.6	56
218	Clonal Hematopoiesis and Myeloid Neoplasms in the Context of Telomere Biology Disorders. <i>Current Hematologic Malignancy Reports</i> , 2022, 17, 61-68.	1.2	14
219	Clonal Hematopoiesis Is Associated with Increased Risk of Severe Neurotoxicity in Axicabtagene CiloleuceL Therapy of Large B-Cell Lymphoma. <i>Blood Cancer Discovery</i> , 2022, 3, 385-393.	2.6	29
220	DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES: ANALOGIES AND DIFFERENCES. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2022, 14, e2022030.	0.5	2
221	PPM1D in Solid and Hematologic Malignancies: Friend and Foe?. <i>Molecular Cancer Research</i> , 2022, 20, 1365-1378.	1.5	6
222	The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. <i>Leukemia</i> , 2022, 36, 1703-1719.	3.3	1,211
224	Game of clones: Diverse implications for clonal hematopoiesis in lymphoma and multiple myeloma. <i>Blood Reviews</i> , 2022, 56, 100986.	2.8	6
225	Routine clinical parameters and laboratory testing predict therapy-related myeloid neoplasms after treatment for breast cancer. <i>Haematologica</i> , 2023, 108, 161-170.	1.7	2
226	International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. <i>Blood</i> , 2022, 140, 1200-1228.	0.6	814
227	Elevated Mutational Age in Blood of Children Treated for Cancer Contributes to Therapy-Related Myeloid Neoplasms. <i>Cancer Discovery</i> , 0, , OF1-OF14.	7.7	5
228	Past, present and future in low-risk myelodysplastic syndrome. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	0
229	Molecular Pathways in Clonal Hematopoiesis: From the Acquisition of Somatic Mutations to Transformation into Hematologic Neoplasm. <i>Life</i> , 2022, 12, 1135.	1.1	6
230	CHIPing away the progression potential of CHIP: A new reality in the making. <i>Blood Reviews</i> , 2023, 58, 101001.	2.8	6
231	EGR1 Haploinsufficiency Confers a Fitness Advantage to Hematopoietic Stem Cells Following Chemotherapy. <i>Experimental Hematology</i> , 2022, 115, 54-67.	0.2	2
232	Characterization of therapy-related acute myeloid leukemia: increasing incidence and prognostic implications. <i>Haematologica</i> , 2023, 108, 1015-1025.	1.7	13
233	Immunogenomic profiling of lung adenocarcinoma reveals poorly differentiated tumors are associated with an immunogenic tumor microenvironment. <i>Lung Cancer</i> , 2022, 172, 19-28.	0.9	9
234	Genome-Based Medicine for Acute Myeloid Leukemia: Study and Targeting of Molecular Alterations and Use of Minimal Residual Disease as a Biomarker. <i>Hemato</i> , 2022, 3, 543-568.	0.2	0

#	ARTICLE	IF	CITATIONS
235	The development of therapy related myeloid neoplasms in childhood cancer survivors. Trends in Cancer, 2022, 8, 790-791.	3.8	0
236	Novel epigenetic therapeutic strategies and targets in cancer. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2022, 1868, 166552.	1.8	8
237	Clonal Hematopoiesis of Indeterminate Potential in Patients with Solid Tumor Malignancies. Cancer Research, 2022, 82, 4107-4113.	0.4	8
238	CLONAL HEMATOPOIESIS: ROLE IN HEMATOLOGIC NON-HEMATOLOGIC. Mediterranean Journal of Hematology and Infectious Diseases, 2022, 14, e2022069.	0.5	1
239	Epidemiologic outlook of therapy-related myeloid neoplasms and selection of high-risk patients: A Korean nationwide study. Cancer, 0, , .	2.0	0
241	Cardiac computed tomographic imaging in cardio-oncology: An expert consensus document of the Society of Cardiovascular Computed Tomography (SCCT). Endorsed by the International Cardio-Oncology Society (ICOS). Journal of Cardiovascular Computed Tomography, 2023, 17, 66-83.	0.7	21
242	Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience. Clinical Cancer Research, 2022, 28, 5211-5220.	3.2	7
243	The International Consensus Classification of myelodysplastic syndromes and related entities. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2023, 482, 39-51.	1.4	6
245	Clonal hematopoiesis in patients with stem cell mobilization failure: a nested case-control study. Blood Advances, 0, , .	2.5	0
246	Clonal hematopoiesis and bone marrow inflammation. Translational Research, 2023, 255, 159-170.	2.2	3
247	Factors associated with clonal hematopoiesis and interaction with marrow environment. Journal of Bone and Mineral Metabolism, 0, , .	1.3	0
248	CHIP Happens: Clonal Hematopoiesis of Indeterminate Potential and Its Relationship to Solid Tumors. Clinical Cancer Research, 2023, 29, 1403-1411.	3.2	9
249	Comparison of the International Consensus and 5th WHO edition classifications of adult myelodysplastic syndromes and acute myeloid leukemia. American Journal of Hematology, 2023, 98, 481-492.	2.0	11
252	Clinical and molecular spectrum and prognostic outcomes of U2AF1 mutant clonal hematopoiesis- a prospective mayo clinic cohort study. Leukemia Research, 2023, 125, 107007.	0.4	6
254	Liquid biopsy: a right tool in a right context?. , 2023, , 31-45.		0
255	Therapy-selected clonal hematopoiesis and its role in myeloid neoplasms. Leukemia Research, 2023, 126, 107020.	0.4	0
256	Analysis of clinical and genomic profiles of therapy-related myeloid neoplasm in Korea. Human Genomics, 2023, 17, .	1.4	1
257	Analysis of the differential expression and prognostic relationship of DEGs in AML based on TCGA database. European Journal of Medical Research, 2023, 28, .	0.9	1

#	ARTICLE	IF	CITATIONS
258	Revisiting the inhibitory potential of protein kinase inhibitors against NEK7 protein via comprehensive computational investigations. <i>Scientific Reports</i> , 2023, 13, .	1.6	5
259	Therapy-related MDS dissected based on primary disease and treatmentâ€™a nationwide perspective. <i>Leukemia</i> , 2023, 37, 1103-1112.	3.3	1
260	Immunologic Predictors for Clinical Responses during Immune Checkpoint Blockade in Patients with Myelodysplastic Syndromes. <i>Clinical Cancer Research</i> , 2023, 29, 1938-1951.	3.2	2
261	Updates in molecular genetics of therapy-related myeloid neoplasms. <i>Seminars in Diagnostic Pathology</i> , 2023, , .	1.0	0
278	Clonal haematopoiesis - a novel entity that modifies pathological processes in elderly. <i>Cell Death Discovery</i> , 2023, 9, .	2.0	0
282	Management of Acute Myeloid Leukemia with Myelodysplasia-Related Changes and Therapy-Related Acute Myeloid Leukemia. , 2023, , 119-128.		0
283	Therapy-Related MDS/AML and the Role of Environmental Factors. , 2023, , 409-420.		0
284	Clonal Hematopoiesis and Its Functional Implications in MDS/AML. , 2023, , 405-407.		0